AstraZeneca Q4 Earnings Beat, Sales Hurt By COVID Jab By: TalkMarkets February 09, 2023 at 08:23 AM EST Core earnings of $1.38 per share declined 17% year over year on a reported basis and 5% at constant exchange rates (CER). Read More >> Related Stocks: Astrazeneca Plc ADR Merck & Co